An open-label, dose-escalation study to assess the tolerability and pharmacokinetics of CB 189625 in healthy volunteers.

Trial Profile

An open-label, dose-escalation study to assess the tolerability and pharmacokinetics of CB 189625 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs CB 189625 (Primary)
  • Indications Acute pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jan 2013 Status changed from planning to recruiting.
    • 11 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top